Shohei Andoh1, Junya Makiyama1, Mai Mizusawa1, Kanya Kondoh1, Toyotaka Kawamata1, Kazuaki Yokoyama1, Tomohiko Koibuchi2, Hiroshi Yasui1, Yasunori Ota3, Yoichi Imai1, Hiroshi Yotsuyanagi2, Arinobu Tojo1 (1.Department of Hematology / Oncology, IMSUT hospital, Tokyo, Japan., 2.Department of Infectious Diseases and Applied Immunology, IMSUT hospital., 3.Department of Pathology and Laboratory Medicine, IMSUT hospital.)
Session information
Oral Session
Oral Session 3-7C Malignant Lymphoma: Advese events/Others
Sun. Oct 14, 2018 1:50 PM - 2:50 PM No.7 (Osaka International Convention Center, 10F 1001)
Chair: Koji Kato (Kyushu University Hospital Hematology, Oncology& Cardiovascular Medicine, Japan)
【E】
Shotaro Hagiwara1, Masayuki Shiseki1, Kentaro Yoshinaga1, Junji Tanaka1, Seiji Okada2 (1.Hematol, Tokyo Women's Medical University, Japan, 2.AIDS Research Center Kumamoto University, Japan)
Daisuke Kaji1,2, Michiho Ebihara1, Mitsuhiro Yuasa1, Kosei Kageyama1, Aya Nishida1, Shinsuke Takagi1, Hisashi Yamamoto1, Yuki Asano-Mori1, Naoyuki Uchida1, Yasunori Ota3, Koji Izutsu1,4, Shigeru Chiba5, Shuichi Taniguchi1, Go Yamamoto1 (1.Department of Hematology, Toranomon Hospital, Tokyo, Japan, 2.Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 3.Department of Pathology, The University of Teikyo, Tokyo, Japan, 4.Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 5.Department of Hematology, University of Tsukuba, Tsukuba, Japan)
Ferania Mella1, Yasuhiro Yamashiro1, Yuki Amao1, Fukumi Ohto1, Shizuka Ogata1, Kazuhiko Muraki2, Naoki Fujita2, Junko Okita3, Yukiko Torii3, Yukio Hattori3 (1.Ube, Japan, 2.Internal Medicine Department, Yamaguchi Saisekai General Hospital, Yamaguchi, Japan, 3.Inspection Department, Yamaguchi Saisekai General Hospital, Yamaguchi, Japan)
Hui-Hua Hsiao1, Yu-Fen Tsai1, Jeng-Shiun Du1, Ming-Hui Lin1, Shih-Hao Tang1, Hui-Ching Wang1, Shih-Feng Cho1,2, Chiung-Tang Huang1, Jui-Feng Hsu1, Yi-Chang Liu1,2, Samuel Y Hsiao1, Chia-Yen Dai1,2, Ming-Lung Yu1,2, Ta-Chih Liu1,2 (1.Internal Medicine Department, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 2.Faculty of Medicine, Kaohiung Medical University, Kaohsiung, Taiwan)
Takaaki Chou1, Kazuhito Yamamoto2, Toshihiko Doi3, Yasuhito Terui4, Harumi Kato2, Takayuki Hirose1, Sachiko Seo5, Yumi Ogaki6, Hiroshi Fujimoto6, Tomoko Ohtsu6, Kiyohiko Hatake7 (1.Department of Hematology Oncology, Niigata Cancer Center Hospital, Niigata, Japan, 2.Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan, 3.Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan, 4.Department of Hematology Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, 5.Department of Hematology and Oncology, National Cancer Center Hospital East, Chiba, Japan, 6.Celgene K. K., Tokyo, Japan, 7.Department of Hematology, International University of Health and Welfare, Mita, Tokyo, Japan)